Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/314821

Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment

Description:

As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of comarketing these combinations. This two-part series is designed to showcase fundamental considerations in diagnostic/drug comarketing plans. Part 1 of this series examined the potential benefit that drug companies can gain from entering into well-planned marketing collaborations with diagnostics companies and presented a framework on which to build these collaborations. In Part 2, we focus on the importance of the financial justification for those collaborations. To highlight the importance of this analysis, we discuss the variables that must be considered when quantifying the expected return. We review three hypotheses often encountered when determining the benefit of a diagnostic, applying to them historical cases in which the relationships between diagnosis and treatment can be measured or analyzed and used as benchmarks when estimating the financial return on new ventures.

Business Implications
- With a broad range of targeted therapies requiring the use of a diagnostic coming to market, comarketing of diagnostics and therapies will become routine. Although theranostics and personalized medicine promise to change the pharmaceutical business model, pharmaceutical companies have little experience in commercializing and marketing diagnostics.
- Pharmaceutical companies need to learn that diagnostics, like the more familiar pharmacotherapies, respond to long-range planning,
branded marketing strategies, and direct selling. Diagnostics can also, in a wide range of circumstances, enhance a therapy’s life-cycle and provide a more-predictable return on marketing investment.
- Although the recent growth in targeted therapy has encouraged the tandem delivery of diagnostics and therapeutics to the physician’s
office, joint sales teams are still not widely employed. Until the economics of a shared salesforce is explored in the field, the responsibility for organizing direct detailing of the diagnostic will be borne by the diagnostics partner.
- The pharma industry should not hesitate to take an early, active role in the collaboration to deliver integrated care. A logical approach
integrating pharma’s creative marketing skills could expand the market, help patients, and provide for better economic returns fo both pharma and diagnostics

Contents:

Introduction
Reasons for Calculating the Return on Investment
Estimates of Return
Using Case-Based Reasoning to Calculate the Return on Investment
The Diaceutics Model
Variable
Analyzing Scenarios Using Case-Based Reasoning
Hypothesis 1: A Related Diagnostic Will Accelerate the Uptake of a Novel Drug in Clinical Areas Where Diagnosis Is Difficult
Hypothesis 2. A Related Monitoring Test Will Improve Patient Compliance with a
Drug That Requires Long-Term Use
Hypothesis 3. A Well-Managed Diagnostic Program Can Justify Premium Pricing, Offsetting Restrictions in the Size of the Patient Pool
Evaluating a Diagnostic Partnership

List of Tables and Figures

Table 1. Direct and Indirect Variables Used in Case-Based Reasoning
Table 2. Select Therapies and Associated Diagnostic Tests
Figure 1. Effect on Revenue of Select Therapies from Increased Patient Compliance

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/314821

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 29/11/2009 01:44:49

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment
Web Address:
http://www.researchandmarkets.com/reports/314821
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

	Format	Quantity	Price
	Electronic (PDF) - Single User		€680.00

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 29/11/2009 01:44:49

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)